A letter from our desk HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Since the start of the year, Cannabis Bioscience…
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia Approximately 10 million adults in…
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,…
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a…
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical…
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for…
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted…
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and…
PDF Version LYON, France, July 8, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader…
TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million…